ADAMA Ltd.

ADAMA is the world's leading pure-play off-patent crop protection company and the "value" arm of Syngenta Group. It does not discover new chemistry at the scale of the research majors; instead it takes active ingredients that have lost or are about to lose patent protection and re-engineers them through proprietary formulation platforms (Asorbital, Sesgama, T.O.V., Desidro, Ayalon) into mixtures that offer growers a measurable agronomic benefit at a lower price point than originator brands. It sells roughly USD 4 billion a year of herbicides, insecticides and fungicides, with a balanced footprint across Europe, North America, Latin America and Asia-Pacific, backed by back-integrated synthesis in Israel, China and Brazil. After a severe 2023–2024 downturn caused by channel destocking and Chinese active-ingredient overcapacity, the "Fight Forward" programme has restored margins and cash generation, although statutory earnings only turned positive in the first half of 2026 and leverage remains elevated.

What the company says. In its results releases ADAMA describes itself as a global crop protection leader that supplies practical solutions to farmers for weeds, insects and disease, built on a diverse portfolio of existing active ingredients, formulation capability and proprietary formulation technology platforms. It states that it serves customers in dozens of countries with a direct presence in all of the top 20 agricultural markets (FY2025 PR, "About ADAMA"). Earlier boilerplate (FY2022 PR) referred to sales in more than 100 countries; the narrower current wording is consistent with the Fight Forward decision to concentrate on priority countries.

Independent characterisation. ADAMA is an integrated post-patent agrochemical manufacturer and marketer. Its economics rest on four activities:

1. Registration and regulatory work. Value in off-patent crop protection is gated by product registrations country by country. ADAMA obtained 174 new registrations in 2025 and maintains a registration network covering more than 80 countries (2025 Annual Report, as summarised by Sohu Finance and Dongxing Securities).

2. Formulation and mixture design. The company manages more than 300 active ingredients centrally and about 1,300 end-use mixtures and formulations (Dongxing Securities note of 7 April 2026, citing the 2025 Annual Report). "Differentiated" products accounted for 45% of crop protection sales excluding active-ingredient sales in 2025.

3. Manufacturing. Synthesis of selected active ingredients and formulation at sites principally in Israel, China and Brazil (FY2025 PR). The company has moved away from producing certain basic chemicals in China and is explicitly shifting to a more flexible, asset-light supply network (H1 2026 PR).

4. Go-to-market. Sales are made mainly to distributors, retailers and cooperatives, with farmer-facing demand generation in priority markets. A smaller Consumer & Professional Solutions business in North America sells home, garden and professional pest-control products.

Revenue model. Revenue is almost entirely product sales. There is no material subscription, licensing or service revenue disclosed; the December 2025 BASF agreement on Gilboa introduces a co-development and commercialisation arrangement whose financial terms are not publicly disclosed. In FY2025, Crop Protection contributed USD 3,730 million (92%) and Intermediates & Ingredients USD 321 million (8%) (FY2025 PR).

Value chain position. ADAMA sits between upstream chemical intermediates suppliers (largely Chinese) and agricultural distribution. It is partially back-integrated into chlor-alkali and key intermediates, and buys a significant share of technical-grade active ingredients externally. This makes gross margin sensitive to the timing gap between falling procurement costs and falling selling prices, visible in the margin compression of 2023 and the recovery of 2024–2025.

Customers and end-markets. End-users are growers of row crops (soybean, corn, cereals, cotton, rice, sugarcane), fruit and vegetables, and speciality crops. Non-agricultural customers include consumer and professional pest-control channels in North America and industrial buyers of intermediates, aroma chemicals and other non-ag products.

Fight Forward (2024–2026)

Launched in early 2024 as a three-year transformation plan to deliver progressively better profit and cash (FY2024 PR). Its three pillars, in the company's framing, were:

1. Optimise financial management: cost reduction, commercial excellence and manufacturing excellence.

2. Streamline the operating model: focus on key geographies and centralise global functions so country teams concentrate on customers.

3. Focus on the "Value Innovation" segment: off-patent actives upgraded with proprietary formulation technology that delivers tangible grower benefits such as rainfastness, better leaf penetration and ease of use.

No quantified public targets (for example an EBITDA margin or savings figure) were found in the results releases. Outcomes to date: adjusted EBITDA margin up from 8.7% (2023) to 14.5% (2025); free cash flow from -USD 147 million to +USD 269 million; adjusted net income restored to profit. Cumulative restructuring and advisory costs were USD 40 million (2024), USD 62 million (2025) and USD 6 million (H1 2026).

Next phase (2026 onward)

Management describes 2026 as the move from stabilisation to profitable growth, with selective growth in markets and offerings where returns are attractive. The four stated sources of value (H1 2026 PR) are:

1. Portfolio differentiation that meets grower needs.

2. Stronger commercial capabilities.

3. A more competitive, flexible and asset-light supply and manufacturing network.

4. Better organisational design, processes and systems.

Financial targets and guidance

ADAMA does not publish numerical revenue or earnings guidance. The only forward-looking quantified disclosure located was the statutory H1 2026 profit pre-announcement (net profit attributable of RMB 364–501 million), subsequently met at RMB 432.6 million. Medium-term financial targets: not publicly disclosed.

ADAMA's catalogue exceeds 1,300 formulations and cannot be enumerated from public sources. The register below covers every product named in company results releases from FY2022 to H1 2026, which is where the company itself identifies its flagship and differentiated offerings. Pricing is not disclosed for any product.

Non-crop businesses

Consumer & Professional Solutions (North America) sells home-and-garden and professional pest-control products, including private-label supply; the Bonide and Control Solutions brands are associated with this unit [NV]. Intermediates and Ingredients sells industrial intermediates and aroma/fine chemicals; individual products are not itemised in public results material.

All figures USD million unless stated, from the company's FY2022, FY2023, FY2024 and FY2025 results releases.

Income statement

Basic and diluted EPS are identical in every year (2,329.8 million shares). No dividend was declared for FY2024 or FY2025 (2024 and 2025 Annual Reports); FY2023 was a loss year and is shown as zero on that basis [NV].

Margins and growth

Revenue CAGR FY2021–FY2025: about -4.2% a year (USD). From the FY2022 peak the three-year CAGR is about -10.1%.

Balance sheet (abridged, period-end)

"Total financial debt" and "net debt" are computed here from the abridged balance sheet (bank loans, current maturities and debentures less cash) and are not company-defined measures. The rise in short-term borrowings in 2025 coincides with a USD 329 million fall in "other long-term liabilities" and a USD 183 million fall in debentures, so part of the movement reflects reclassification to current and the bond buyback being funded with shorter bank debt rather than new net borrowing. At 30 June 2026: cash USD 427 million, short-term loans USD 1,403 million, long-term loans USD 169 million, debentures USD 754 million, equity USD 2,589 million, total assets USD 6,849 million (H1 2026 PR).

Cash flow

No share buyback programme has been disclosed in the period; the buyback in 2025 was of subsidiary debentures, not equity.

Commentary

Revenue. The 2022 peak was a price phenomenon: sales rose 16% on 16% higher prices and 4% volume growth as growers absorbed cost pass-through (FY2022 PR). The unwind was equally price-led. In 2023 prices fell 8% and volumes 7% as distributors destocked; in 2024 prices fell a further 8% on flat volumes; in 2025 prices fell 2% with stable volumes (FY2023, FY2024, FY2025 PRs). Price erosion is therefore decelerating but has not ended: H1 2026 prices were down 4% against a 1% volume gain (H1 2026 PR).

Gross margin. Adjusted gross margin fell from 29.3% in 2021 to 22.7% in 2023 as high-cost inventory was sold into falling prices, then recovered to 29.4% in 2025 and 30.1% in H1 2026. The recovery came from cheaper inventory, better mix and operational efficiency rather than pricing. That distinction matters: procurement-cost tailwinds are finite, and H1 2026 already showed mild cost increases.

Operating expenses. Adjusted opex fell in absolute terms from USD 1,107 million in 2022 to USD 850 million in 2024, then edged up to USD 863 million in 2025 on performance-linked pay, currency and LATAM credit-loss provisions. The opex ratio of 21.3% is higher than at the 2022 peak because revenue has fallen faster than cost.

Below the line. Financial expenses are the critical drag. Adjusted financing costs of USD 261 million in 2025 absorbed 79% of adjusted EBIT. Drivers are CPI-linked shekel debentures, hedging costs on the shekel and Turkish lira, and bank interest. The tax line has been perverse: losses sit in entities that cannot recognise deferred tax assets while profitable subsidiaries pay higher rates, producing a USD 133 million adjusted tax charge on a pre-tax loss in 2024.

Reported versus adjusted. The gap between reported and adjusted net income was USD 201 million in 2024 and USD 175 million in 2025. In 2025 it comprised restructuring and advisory costs (USD 62 million), asset and inventory impairments (USD 55 million), Syngenta transfer-asset amortisation (USD 22 million), PPA amortisation (USD 14 million), remediation (USD 14 million), put-option revaluation (USD 16 million), a debenture buyback loss (USD 9 million), partly offset by product-liability compensation income (USD 25 million). Restructuring and impairment charges have recurred for two consecutive years; investors should treat a portion as a structural cost of the footprint reset.

Cash. Cash generation is the clearest success. Free cash flow swung from an outflow of USD 417 million in 2022 to inflows of USD 217 million in 2024 and USD 269 million in 2025, driven by inventory reduction (USD 1,848 million to USD 1,553 million during 2024), collections and extended payables. Inventory was rebuilt by about USD 100 million in 2025 ahead of the Israeli entity merger and to capture demand. H1 2026 free cash flow of USD 54 million (against USD 90 million) shows the working-capital release is largely complete.

Management stance. No numerical guidance. Management's qualitative message in August 2026 is that underlying demand is healthy with low channel stocks, pricing remains under pressure from Chinese overcapacity and weak farmer income, and the company will prioritise margin, cash and selective growth. The effect of the Israeli security situation and of tariffs is described as immaterial.

Consensus. Net profit of about RMB 333 million for 2026 (two brokers), against a 2025 loss of RMB 1,046 million.

Bull case

1. Self-help is proven and not exhausted. EBITDA margin has risen almost six points in two years; the asset-light programme, entity merger and falling restructuring charges (USD 6 million in H1 2026 against USD 29 million) should narrow the gap between adjusted and reported earnings.

2. Financing costs are falling. Adjusted financial expenses dropped from USD 348 million (2023) to USD 261 million (2025) and a further 13% in H1 2026; each USD 50 million saved roughly doubles 2025 adjusted pre-tax profit.

3. Innovation optionality is under-priced at 0.7x book. Gilboa and Feralla give an off-patent company two proprietary actives, one endorsed by BASF, while a strong run of diamide, prothioconazole and pinoxaden products refreshes the core.

Bear case

1. Price deflation is structural. Four years of declining prices with management itself calling Chinese overcapacity structural; gross margin gains came from cost, which is now turning up.

2. The balance sheet leaves little margin for error. About USD 1.4 billion of short-term borrowings, interest cover near 1.3x, and free cash flow that halved in H1 2026 as working capital stopped releasing.

3. Earnings quality and governance. H1 2026 profit included a USD 36 million property gain; three years of large "non-recurring" charges; a controlling shareholder that rotates management according to group needs and pays no dividend to minorities.

Catalysts and monitorables (next 12 months)

• Q3 2026 results (late October 2026) and FY2026 results (March 2027): whether the second half stays profitable.

• Price trend: first quarter of flat or positive pricing.

• Strategic priorities set out by Dr. Hao after 1 November 2026; any reset of Fight Forward targets.

• Gilboa approvals in the UK and EU and the terms of BASF commercialisation.

• Ferrabait roll-out across EU member states.

• Short-term debt refinancing and any new debenture issue; S&P Maalot review.

• Security developments affecting Neot Hovav, Ashdod and port logistics.

• Shekel exchange rate and Israeli CPI.

• Any revival of Syngenta Group's listing plans or change in ADAMA's status within the group.

• Dividend decision for FY2026.

Analyst verdict

ADAMA in late 2026 is a company that has been fixed operationally but not yet financially. The Fight Forward programme did what it set out to do: adjusted EBITDA is back at USD 587 million on a revenue base USD 1.5 billion smaller than at the 2022 peak, gross margin has returned to pre-crisis levels above 29%, and two consecutive years of solid free cash flow have stabilised the balance sheet. The first half of 2026 produced the first statutory profit since 2022.

The harder question is what the business earns in a normal year. Stripping out the property gain, first-half 2026 adjusted EBITDA was slightly lower than a year earlier, prices are still falling, and operating expenses are rising again. Almost four-fifths of adjusted operating profit goes to lenders. On that evidence ADAMA's sustainable net margin is in the low single digits, which is thin for a business carrying conflict-zone manufacturing risk, emerging-market credit exposure and a currency mismatch.

Against this, the franchise is stronger than the share price implies. Few competitors can match its registration estate, its formulation patents or its balanced geography, and none of its off-patent peers has a new mode-of-action fungicide with a research major as partner. Syngenta Group's ownership caps the downside on funding even as it limits minority shareholders' influence.

The incoming CEO inherits a stabilised platform and a clear to-do list: convert volume growth into pricing power through differentiated products, cut interest cost by terming out and reducing debt, and stop the recurring restructuring charges. If he delivers two of the three, the equity, valued at roughly six times EBITDA and well below book, has meaningful upside. If pricing deteriorates further, leverage will again dominate the story. On balance the risk-reward is moderately favourable but dependent on execution, with the second-half 2026 results the first real test.

Principal sources: ADAMA Ltd. results press releases for FY2022 (20 March 2023), FY2023 (March 2024), FY2024 (13 March 2025), FY2025 (27 March 2026), Q1 2026 (29 April 2026) and H1 2026 (18 August 2026); ADAMA 2024 and 2025 Annual Reports and 2025 ESG Report (SZSE); Q1 and H1 2025 reports; board announcement 2025-22; ADAMA board-of-directors and supplier-merger web pages; company press releases of 5 December 2024, 18 December 2025, 27 April 2026, 7 May 2026 and 18 September 2026; S&P Maalot issuer page; Xueqiu, Tonghuashun and Investing.com market data; Farmers Weekly, The Scottish Farmer, Indian Chemical News, AgriBusiness Global and Global Agriculture trade coverage.

Layoffs: workforce restructuring is part of Fight Forward (restructuring costs recognised) but headcount reduction numbers are not publicly disclosed in the reviewed material. Guidance revisions: none, as no guidance is issued.